MedTrace Logo

Turkish Version of Childhood Bladder and Bowel Dysfunction Questionnaire

NCT03742570 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2018-11-19

No results posted yet for this study

Summary

Objectives:The aim of this study was to translate the Childhood Bladder and Bowel Dysfunction Questionnaire into Turkish, adapt it for use with parents of 5-12 year old children and determine the reliability and construct validity of the Turkish version. The main hypothesis of our study was that it would be possible to translate and culturally adapt the CBBDQ into a Turkish version, so that Turkish parents could understand it. Additionally, we hypothesized that the Turkish version would provide adequate internal consistency and test-rest reliability and acceptable construct validity.

Methods:The Childhood Bladder and Bowel Dysfunction Questionnaire was guideline driven translated into Turkish and administered twice, at 7-day intervals, to parents of children to assess test-retest reliability. Cronbach's α was used for internal consistency and the inter-rater correlation coefficient was used to calculate test-retest reliability. The Dysfunctional Voiding and Incontinence Scoring System (DVISS) and Pediatric Quality of Life Inventory (PedsQL) in 5-7, 8-12 years old children were used as an external criterion to estimate construct validity.

Conditions

  • Children

Interventions

BEHAVIORAL

CBBDQ

a questionnaire for childood bladder and bowel dysfunctions

Sponsors & Collaborators

  • Okan University

    lead OTHER

Principal Investigators

  • Gamze Aydin, MSc · Okan University

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-13
Primary Completion
2018-06-15
Completion
2018-10-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03742570 on ClinicalTrials.gov